RecruitingPhase 3NCT06456489

Pulse Steroid Injection in Refractory Rheumatoid Arthritis

Revealing the Potential of Intravenous Pulse Steroid Therapy; Impressive Results in Attaining Remission or Low Disease Activity in Refractory Rheumatoid Arthritis


Sponsor

Sohag University

Enrollment

268 participants

Start Date

May 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Remission or low disease activity in active rheumatoid arthritis


Eligibility

Min Age: 20 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether high-dose steroid injections (given as "pulse" therapy) can help people with rheumatoid arthritis (RA) whose disease has not responded adequately to other treatments — known as refractory RA. **You may be eligible if...** - You have been diagnosed with rheumatoid arthritis - Your RA has not responded well to standard treatments (refractory) **You may NOT be eligible if...** - You have other connective tissue diseases (such as lupus or Sjögren's syndrome) - You have certain hormonal/metabolic conditions such as diabetes or thyroid disorders Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSolumedrol

125 mg methylprednisolone intravenous pulse on 2 consecutive days


Locations(1)

Al-Azhar Univrsity

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06456489


Related Trials